EMA gives IMPD approval to initiate Ph 1 trial of OT-C001 + Rituximab in DLBCL patients April 30, 2025
Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee’s assessment of cohort 1 April 22, 2025
First Patient enrolled in Ph 2 Trial of Ethanol-Free Carmustine in High-Dose Chemotherapy Prior to Transplant in Patients with HL or NHL April 22, 2025
PTX-100 receives US FDA Fast Track Designation for the treatment of adults with R/R mycosis fungoides, the most common subtype of CTCL April 22, 2025
BORUZU, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma, launched April 8, 2025
Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP for 1L MCL April 2, 2025
Update relating to Resminostat’s (Kinselby) Marketing Authorisation Application announced March 18, 2025
U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia March 18, 2025
Clinical Trial Application Submitted in Australia for CS5001 in Combination with 1L SOC for DLBCL March 11, 2025
First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort March 4, 2025
EPKINLY® (epcoritamab) Approved by Japan MHLW for Additional Indication as a Treatment for R/R Follicular Lymphoma February 25, 2025
Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with R/R MZL Announced February 19, 2025
Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated February 11, 2025
